2024 Research & Development Revenue of $30 Million Successful Results from the US Burn Validation Study On Track for Regulatory Submission in US for DeepView™ System DALLAS, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence ("AI") company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter ("Q4 2024") and full year ("FY 2024") ended December 31, 2024, and provided an update on its ongoing business activities. "Spectral AI achieved much in 2024. Our top-l

DALLAS, March 24, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the successful completion of a debt financing agreement of up to $15.0 million in funding from Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, with an initial draw down of $8.5 million. In connection with this debt financing, the Company also raised $2.7 million of equity financing from institutional as well as existing investors. With total cash on hand now of over $14 million and potential access t

DALLAS, March 20, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ:MDAI) ("Spectral AI" or the "Company"), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced that its wholly-owned subsidiary,  Spectral IP, Inc., has publicly filed a registration statement with the U.S. Securities and Exchange Commission ("SEC") relating to its planned spinoff through an initial public offering of its shares of common stock. Spectral IP, Inc. will be renamed SIM IP Inc. ("SIM IP") prior to the completion of this offering.

DeepView® System outperforms burn physicians in identifying non-healing tissue Landmark Burn Validation Study, one of the largest in U.S. history, confirms DeepView's performanceSpectral AI plans FDA submission by mid-2025, targeting De Novo Clearance and rapid commercialization to transform burn care DALLAS, March 17, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ:MDAI) ("Spectral AI" or the "Company"), developer of the AI-driven DeepView® System, that uses multi-spectral imaging and AI algorithms to predict burn healing potential, announced the successful results of the performance of its DeepView System in connection with the completion of its Burn Validation Study. Spectral AI's DeepV

DALLAS, March 06, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ:MDAI) ("Spectral AI" or the "Company"), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration ("FDA") in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the completion of the installation of three of the DeepView System devices in Australia.   The Company, in partnership with global medical device company and burn wound therapy leader PolyNovo Limited ("PolyNovo"). The Company was able to utilize the Australian Special Access Scheme (SAS) to deploy three DeepView Systems at the Concord Repat

DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ:MDAI) ("Spectral AI" or the "Company"), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration ("FDA") in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 27, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results. Investors interested in participating in the live call can dial: 844-481-30

DALLAS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ:MDAI) ("Spectral AI" or the "Company"), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration ("FDA") in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the satisfaction of its final remaining obligations under the Company's debt facility with Yorkville Advisors. The Company retains access to additional financing of up to $17.5 million under an existing standby equity purchase agreement. "I am pleased to share this milestone as we continue advancing toward our FDA submission and work to brin

USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Feb. 11, 2025 /PRNewswire/ -- USA News Group News Commentary – Weeks after the monumental $500-billion announcement of Project Stargate, which includes aims to transform healthcare, a growing number of health executives are seeing the promise of Artificial Intelligence (AI) in their industry. A recent poll from Deloitte found that 40% of health execs say generative AI (genAI) pays off for their businesses. Early in 2025, it's becoming clearer that genAI is revolutionizing diagnostics, enhancing treatment options, and personalizing patient care. Beyond Stargate's big players, a growing number of innovator

DALLAS, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ:MDAI) ("Spectral AI" or the "Company"), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration ("FDA") in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the completion of its data analytics for its U.S. Burn Pivotal Study.   One of the largest domestic burn studies ever conducted, the U.S. Burn Pivotal Study is designed to validate the AI-driven algorithm used by the Company's DeepView® System for its burn indication. Spectral AI's DeepView® System is a predictive medical device and associate

DALLAS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ:MDAI) ("Spectral AI" or the "Company"), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced the completion of its pediatric enrollment at U.S. emergency departments for its U.S. Burn Pivotal Study. One of the largest domestic burn studies ever conducted, the U.S. Burn Pivotal Study is designed to validate the AI-driven algorithm used by the Company's DeepView™ System for burn indication. Using data from these burn center patients, the Company will pursue a De Novo

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

DALLAS, May 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective following the closing of US equity markets on Friday, June 28, 2024 according to a preliminary list of additions posted Friday, May 24, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, 2024 ranking them by total market capitalization. Members

DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2024 Annual Meeting of Stockholders held on May 14, 2024 (the "AGM"). At the AGM, stockholders overwhelmingly approved each of the four proposals set forth by the Company. The voting results are detailed below. Six directors were elected to serve until the next Annual Meeting of Stockholders: Richard Cotton, Chairman of the Company's Board of DirectorsPeter M. Carlson, Chief Executive Officer of the

DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer. Jeremiah has more than 20 years of medical device marketing experience, including global marketing and business strategy. Mr. Sparks will be responsible for both domestic and international product commercialization. "We are thrilled to have Jeremiah join the company as we move towards commercialization of DeepView," said Peter M. Carlson, CEO of Spectral AI.

Appointment Paves the Way for Company's Next Chapter in Commercialization Phase of AI-Powered DeepView Device for Predictive Wound Care Carlson Brings Proven Track Record of Operating and Financial Leadership, Including with Premier Wound Care Management Companies Wensheng Fan Transitions to Chief Innovation Strategist and Senior Advisor to the CEO Company Announces Preliminary 2023 R&D Revenue; Reaffirms Full Year Revenue Guidance for 2024 and Highlights First Quarter Momentum DALLAS, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate tre

DALLAS, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, today announced the appointment of Erich Spangenberg to the Board of Directors ("Board"). Mr. Spangenberg will serve as Chairman of the Company's Executive Committee as well as the Nominating and Corporate Governance Committee. "We are pleased to welcome the return of Erich to the Board of Directors, where his experience, insights and network will be an invaluable resource for our company," said Wensheng Fan, CEO of Spectral AI. "Erich's pro

DALLAS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Prof. Paul Chadwick as Executive Vice President of the Company's United Kingdom subsidiary. Prof. Chadwick is an experienced clinical scientist and wound care key opinion leader (KOL) with an impressive body of work including a substantial and impactful publication record, particularly in the domain of diabetic wound management. He will be responsible for the international market expansion of the Company's DeepView®

DALLAS, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI, MDAIW))) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Deepak Sadagopan, MHCDS, to its board of directors. A high-impact healthcare executive with more than 25 years of senior leadership experience with top Fortune-rated corporations and aggressive startup environments, he brings to the board expertise in healthcare technology and analytics along with a successful track record in product launches. Currently, Mr. Sadagopan is the Chief Operating Officer of Popula

2024 Research & Development Revenue of $30 Million Successful Results from the US Burn Validation Study On Track for Regulatory Submission in US for DeepView™ System DALLAS, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence ("AI") company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter ("Q4 2024") and full year ("FY 2024") ended December 31, 2024, and provided an update on its ongoing business activities. "Spectral AI achieved much in 2024. Our top-l

DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ:MDAI) ("Spectral AI" or the "Company"), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration ("FDA") in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 27, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results. Investors interested in participating in the live call can dial: 844-481-30

Revenue Rose to $8.2 MillionCompany Reaffirms Timeline for Regulatory Submission to U.S. FDA Q3 2024 Overview Research & Development Revenue Rose 138% to $8.2 MillionLast Patient Out at Burn Centers for U.S. Burn Pivotal Study; Top Line Study Results Expected in Q4 2024U.S. FDA Submission on Track for Q2 2025Completed Proof-of-Concept Module for Wound Measurement Technology DALLAS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the third quarter ended S

DALLAS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the third quarter ended September 30, 2024 on Wednesday, November 6, 2024 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results.   Investors interested in participating in the live call can dial: 833-630-1956 - U.S.412-317-1837 - International A simultaneous webcast of the call may be accessed

Second Quarter Revenue Totals $7.5 Million Total Enrollment Exceeds 85% for Burn Center Pivotal U.S. Clinical Trial Q2 2024 Overview Research & Development Revenue of $7.5 MillionCash Position of $6.9 MillionOn Track to Generate First Commercial Revenues in the U.K. Later this YearBurn Pivotal Study Nearing Completion Paving the Way for U.S. FDA Submission in Early 2025Announced Collaboration with PolyNovo Ltd. Providing Introduction to Australian MarketContinued Progress in Handheld Burn Wound Diagnostic TechnologyAdded to Russell Microcap® Index effective July 1, 2024 DALLAS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), a

DALLAS, July 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the second quarter ended June 30, 2024 on Monday, August 12, 2024 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results. Investors interested in participating in the live call can dial: 833-630-1956 - U.S.412-317-1837 - International A simultaneous webcast of the call may be accesse

Q1 Overview Research & Development Revenue of $6.3 MillionImproved Capital Structure Reflected in Cash of $10.2 MillionDeepView AI®-Burn Devices Deployed in UK; Expect Commercial Revenue in 2H 2024 Additional Regulatory Submissions in US and UK for DeepView™ System Expected in 2024 and 2025 DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2024 ("Q1 2024") and provided an update on its ongoing business activities. "During the

DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results. Investors interested in participating in the live call can dial: 833-630-1956 - U.S.412-317-1837 - International A simultaneous webcast of the call may be accessed online from the Event

DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Erich Spangenberg has been appointed as the Chief Executive Officer of its health care IP-focused subsidiary, Spectral IP. "Spectral AI is fortunate that our largest shareholder, Erich Spangenberg, has agreed to assume the CEO role at Spectral IP. Erich has consistently been recognized for his unrivaled track record in global IP investment, monetization, enforcement, acquisition, and licensing," said Pete Carlson, CEO of Spe

2023 Research & Development Revenue of $18.1 Million Expected to Increase to $28.0 Million in 2024 Commercialization Underway with Revenue Expected in 2H 2024 for DeepView AI®-Burn Indication in the UK On Track for Additional Regulatory Submissions in US and UK for DeepView™ System Burn and Diabetic Foot Ulcer Indications DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter ("Q4 2023") and full year ("FY 2023") ended December 31, 2023 and pr